94.02
前日終値:
$94.99
開ける:
$94.27
24時間の取引高:
183.40K
Relative Volume:
0.15
時価総額:
$11.34B
収益:
$2.77B
当期純損益:
$286.61M
株価収益率:
40.01
EPS:
2.35
ネットキャッシュフロー:
$524.11M
1週間 パフォーマンス:
-2.42%
1か月 パフォーマンス:
+5.24%
6か月 パフォーマンス:
-16.26%
1年 パフォーマンス:
-12.93%
Revvity Inc Stock (RVTY) Company Profile
RVTY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RVTY
Revvity Inc
|
94.01 | 11.34B | 2.77B | 286.61M | 524.11M | 2.35 |
![]()
TMO
Thermo Fisher Scientific Inc
|
395.36 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
194.38 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
523.02 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
114.67 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
154.49 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-01 | アップグレード | UBS | Neutral → Buy |
2025-01-10 | ダウングレード | Bernstein | Outperform → Mkt Perform |
2024-12-13 | アップグレード | BofA Securities | Neutral → Buy |
2024-10-15 | アップグレード | Barclays | Equal Weight → Overweight |
2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
2024-07-08 | 開始されました | Leerink Partners | Outperform |
2024-06-03 | 再開されました | Jefferies | Hold |
2024-01-16 | ダウングレード | UBS | Buy → Neutral |
2024-01-04 | アップグレード | Evercore ISI | In-line → Outperform |
2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
2023-09-28 | 開始されました | Bernstein | Outperform |
2023-07-19 | 開始されました | Raymond James | Outperform |
2023-05-23 | 再開されました | Goldman | Buy |
すべてを表示
Revvity Inc (RVTY) 最新ニュース
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
How To Trade (RVTY) - news.stocktradersdaily.com
Are Revvity, Inc.'s (NYSE:RVTY) Mixed Financials Driving The Negative Sentiment? - simplywall.st
Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows - SelectScience
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus By Investing.com - Investing.com Canada
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus - Investing.com
Transcript : Revvity, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Revvity To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET - Nasdaq
Wellington Management Group LLP Has $743,000 Stock Holdings in Revvity, Inc. (NYSE:RVTY) - Defense World
(RVTY) Long Term Investment Analysis - news.stocktradersdaily.com
Revvity gets FDA nod for its automated tuberculosis test - MSN
4 Mass. Rulings You May Have Missed In May - Law360
Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus
New Cancer Testing Standards from Revvity Promise More Accurate Diagnostic Results for Oncology Labs - Stock Titan
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo
Millennium Management LLC Trims Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st
Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus
Revvity, Inc. (NYSE:RVTY) Shares Purchased by Cetera Investment Advisers - Defense World
RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN
Revvity (NYSE:RVTY) Cut to “Hold” at Wall Street Zen - Defense World
Zacks Research Forecasts Revvity’s Q1 Earnings (NYSE:RVTY) - Defense World
Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Technology Networks
Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager
Is Wall Street Bullish or Bearish on Revvity Stock? - inkl
Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus
Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News
Ameriprise Financial Inc. Increases Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus
Element Biosciences Welcomes Dr. Madhuri Hegde to its Board of Directors - Business Wire
Revvity Signals Software Inc. v. Cloud Software Group Inc. - Cornerstone Research
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - GlobeNewswire Inc.
Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings - Yahoo
Revvity at Bank of America 2025 Healthcare Conference: Navigating Tariffs and Growth - Investing.com India
Revvity To Present At Bank Of America Global Healthcare Conference 2025; Webcast At 12:20 PM ET - Nasdaq
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine - Yahoo Finance
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN
Revvity Inc (RVTY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):